Evidence map›Paper›PMID 38388353›Full record

ArticleBMC infectious diseases2024

Prevalence of hepatitis B and C infection and linkage to care among patients with Non-Communicable Diseases in three rural Rwandan districts: a retrospective cross-sectional study.

Tumusime Musafiri, Innocent Kamali, Casmille Kayihura, Jean de la Paix Gakuru, Francoise Nyirahabihirwe, Esdras Nizeyimana, Pilar Kandamage, Placide Habinshuti, Raymond Sekagarura, Jean Damascene Makuza and 5 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 4 countries.

Tumusime MusafiriPartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda. Musafiri-mtumusime@pih.org.
Innocent KamaliPartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Casmille KayihuraDepartment of Public Health, Mount Kenya University, Kigali, Rwanda.
Jean de la Paix GakuruPartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Francoise NyirahabihirwePartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Esdras NizeyimanaPartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Pilar KandamagePartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Placide HabinshutiPartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Raymond SekagaruraMinistry of Health, Butaro District Hospital Cancer Center of Excellence, Burera, Rwanda.
Jean Damascene MakuzaRwanda Biomedical Centre, HIV, STIs, Viral Hepatitis and OVDC Division, Kigali, Rwanda.
Nadine KaremaPartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Janvier SerumondoRwanda Biomedical Centre, HIV, STIs, Viral Hepatitis and OVDC Division, Kigali, Rwanda.
Theoneste NtakirutimanaDepartment of Public Health, Mount Kenya University, Kigali, Rwanda.
Jean d'Amour NdahimanaPartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Dale A BarnhartDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Partners In Health · USMount Kenya University · KERwanda Biomedical Center · RWMinistry of Health · RWUniversity of Nairobi · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRwanda's Hepatitis C elimination campaign has relied on mass screening campaigns. An alternative "micro-elimination" strategy focused on specific populations, such as non-communicable disease (NCD) patients, could be a more efficient approach to identifying patients and linking them to care.

methodsThis retrospective cross-sectional study used routine data collected during a targeted screening campaign among NCD patients in Kirehe, Kayonza, and Burera districts of Rwanda and patients receiving oncology services from the Butaro District Hospital. The campaign used rapid diagnostic tests to screen for Hepatitis B surface antigen (HBsAg) and Hepatitis C antibody (anti-HCV). We reported prevalences and 95% confidence intervals for HBsAg and anti-HCV, assessed for associations between patients' clinical programs and hepatitis B and C, and reported cascade of care for the two diseases.

resultsOut of 7,603 NCD patients, 3398 (45.9%) self-reported a prior hepatitis screening. Prevalence of HBsAg was 2.0% (95% CI: 1.7%-2.3%) and anti-HCV was 6.7% (95% CI: 6.2%-7.3%). The prevalence of HBsAg was significantly higher among patients < 40 years (2.4%). Increased age was significantly associated with anti-HCV (12.0% among patients ≥ 70 years). Of the 148 individuals who screened positive for HbsAg, 123 had viral load results returned, 101 had detectable viral loads (median viral load: 451 UI/mL), and 12 were linked to care. Of the 507 individuals who screened positive for anti-HCV, 468 had their viral load results returned (median viral load: 1,130,000 UI/mL), 304 had detectable viral loads, and 230 were linked to care.

conclusionAnti-HCV prevalence among Rwandan patients with NCD was high, likely due to their older age. NCD-HCV co-infected patients had high HCV viral loads and may be at risk of poor outcomes from hepatitis C. Hepatitis C micro-elimination campaigns among NCD patients are a feasible and acceptable strategy to enhance case detection in this high-prevalence population with elevated viral loads and may support linkage to care for hepatitis C among elderly populations.

Indexed as

Hepatitis BHepatitis CNoncommunicable DiseasesAgedCross-Sectional StudiesHepacivirusHepatitis B Surface AntigensHepatitis C AntibodiesHumansPrevalenceRetrospective StudiesRwandaHepatitis B Surface AntigensHepatitis C AntibodiesHepatitis BHepatitis CMicro-eliminationNon-Communicable DiseasesRwandaScreening campaign

Identifiers

PMID38388353
PMCPMC10885378
OpenAlexW4392109211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.